Reddit Posts
Consider investing in 3 penny stocks that have target gains reaching high approx. 1,5000%.
Strike while it's hot: Uncover the top 3 penny stocks set to soar next week!
AKBA stock jumps on EU nod to approve kidney disorder therapy (NASDAQ:AKBA)
AKBA stock slips as FDA respond to appeal for kidney disease therapy (NASDAQ:AKBA)
Akebia Therapeutics (NASDAQ:AKBA) Receives New Coverage from Analysts at StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Earns Hold Rating from Analysts at StockNews.com
AKBA is going to blow. Not a squeeze yet but .....
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $1.75 Average Price Target from Brokerages
thoughts on $AKBA? looks like its floored a really big upside!
💰💰💰Good morning! #premarket #watchlist 07/1 $AKBA -Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries, $QNRX -canceled extra stock offering, $FRSD - no news, $MOHO - no news.
💰💰💰Good morning! #premarket #watchlist 07/1 $AKBA -Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries, $QNRX -canceled extra stock offering, $FRSD - no news, $MOHO - no news.
💰💰💰Good morning! #premarket #watchlist 07/1 $AKBA -Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries, $QNRX -canceled extra stock offering, $FRSD - no news, $MOHO - no news.
$AKBA is the next $PROG run to $6 but with solid fundamentals of 200M revenue yearly and is trading at 80M MC currently
$AKBA - heavy short interest but makes 200M revenue yearly and Market Cap is 80M currently. Major partnership with Mitsubishi Tanabe and drugs approved in Japan.
$AKBA - the move after the next move
5 Promising Biotech Penny Stocks To Keep An Eye On
Akebia Therapeutics $AKBA - Deep-Dive Due Diligence
Akebia Therapeutics $AKBA - Deep-Dive Due Diligence
$AKBA is about to steal billions in revenue from $AMGN and disrupt the multi billion dollar anemia market 💰💰 READ 👇
Vadadustat is scientifically more reliable than Roxadustat … $AKBA will gain the foothold in the untapped oral anemia treatment market before $FGEN… $FGEN was $40 a share before its FDA flop, and $AKBA is currently at < $3 … now is the time to get in before the march PDUFA date… PT $20 + 💰🔥💰
Akebia Therapeutics $AKBA … revenue + cash on hand is less than market cap, and they have a multi billion dollar drug ( Vadadustat) facing EU and FDA approval 1H 2022 … recently upgraded by analysts and the recipient of multiple institutional buys 🔥💰$FGEN $AMGN
Akebia Therapeutics $AKBA … revenue + cash on hand is less than market cap, and they have a multi billion dollar drug ( Vadadustat) facing EU and FDA approval 1H 2022 … recently upgraded by analysts and the recipient of multiple institutional buys 🔥💰
BUY $AKBA - Great opportunity to get long into the stock
AKBA Stock🔥 Akebia Therapeutics AKBA
$CYCN stikes deal with $AKBA worth up to $585 Million...24 million float (cheapest Alzheimer’s play)
$AKBA buys licensing from $CYCN for Alzheimer's Drug and cornering US CKD market before March PDUFA📈
$AKBA buys liscence from $CYCN for Alzheimer's Drug and is trying to corner US CKD market before March PDUFA
Momentum Watchlist for Tuesday, 06/01/21
$AKBA- NDA acceptance possible catalyst for 1000% jump🚀
$AKBA @ $3.50-PT $20- NDA acceptance catalyst any day now🚀
PSA: Buy AKBA. Do your own DD but the pipeline is good, cash to fund ops for 2 years, and the clincher is the management team. Genzyme and Sanofi well represented across the board. They know what they’re doing.
$AKBA - Akebia Therapeutics - Interesting biotech with upcoming possible FDA approval as a catalyst
$AKBA - Akebia Therapeutics - Interesting biotech with upcoming possible FDA approval as a catalyst
Green Light for $AKBA on Technicals
AKBA- DD Upcoming Catalysts (Drug Seeking NDA from FDA)
Mentions
I kinda like AKBA better. OP have you looked at AKBA?
LWLG and AKBA are in the $3 range. Both are growth stocks with breakthrough technology on the verge of sales and financial success. Study them.
Jesus Christ. All that Non pargraphed WOT and you didnt even bothered to include the ticker symbol. (Upon Googling I think its $AKBA. Someone correct me if I'm wrong.)
AKBA..Anyone have it? Seems like a really good mid and long term play.
AKBA is a must. LAES is a long hold that will retire many many young adults. LXRX is a no brainer BBAI : Been holding for about 6 months. Average cost is $2.90 and I own 25k shares. It's absolutely not too late to get in now. By November 2026, you'll be very happy.
AKBA currently $3.75 ER on Aug. 7th Currently $3.75 sell Aug15 CC for $.09-$.15 cents There's a good chance it is over $5 on August 15, if so: 36% in 13 days If it doesn't reach $5 by Aug, sell the Sept $5 CC for $.20 or more getting 40%+ in 45 days. (It will be over $5 by Oct.) And if you want to hold long-term, you're probably looking at possibly over $10 At some point by years end raise the CC strike as the price goes up if not exc. Reinvest the covered call premium back into the stock, For an even greater % return on your money. 100k+ shares here
AKBA stock lets go! Nasdaq article: <Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?> <AKBA has returned about 104.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.7%>
all im waiting for is AKBA to $4 leggo
I'll trow out SKYX and AKBA for you to look into as well
Yeah. I only have a VERY small amount of bio/pharma stocks. Only one really fucked me. I swung off ICU a few times and made decent cash before it went to shit. AKBA, ALT, and JSPR are still treating me well. I'm only holding Jasper until their data readout, most likely. MBOT had 100% success rates in their studies. But, if they can't scale and get sales, they'll drop just like ICU. that's why I'm only holding on until the FDA news. The rest of my stuff is most tech ... green energy/space/ev in one portfolio. Other 3 are much more diversified and way less speculative. As long as you're not YOLOing everything on a bio, it's not too scary for scalping
https://preview.redd.it/g1oozcbgks7f1.jpeg?width=1206&format=pjpg&auto=webp&s=7076f3adab86b6f4c1fde3eff4f86642fae3b7b8 But AKBA thank me later
Green flag: increasing revenue Q/Q, real assets, backlog, cash runway, 10-Qs with increasing revenue/EBITDA guidance, it recently wasn’t a penny stock, or just has a cool niche product with some options on the stock Red Flags: rampant shilling, decreasing revenue, tiny market cap, no real product or service or future valuation is total bs. Picks this 1H UHG 300% CAPT 300% AMPX 100% TTI 50% GROY 35% Picks 2H TTI NFE IMPP TGB AKBA
Lost 50k on WISH and the next day lost 30k on AKBA because the fda issued a crl, my gf also dumped me also on that same day. I’m surprised I didn’t kill myself.
AKBA up 270% in 1Y and accelerating. Still cheap. https://preview.redd.it/zjzfupg0cc5f1.png?width=1364&format=png&auto=webp&s=c7b288081adc689c5d0de552ccb1511786a959d9
AKBA has been on a rise for 2 years and still under $3. I have some.
Adding to the pile: TOI, AKBA, TALK, MASS, TMRC
Fmst and tmc are 2 iv been riding the last month or so. AKBA also has been doing pretty good for me. HUMA I like but they also bleed cash so that one scares me. Anything cyber security iv been keeping an eye on lately also. Idk if redwire is technically a penny stock but they just scored another contract. Can’t decide what to do with that company
Only one stock to watch: $-AKBA do your own DD
AKBA bout to pop also with a good SEC 10-Q Report just now.
Pharmaceutical time. Akebia therapeutics (AKBA) currently has a billion dollar a year drug on the market that is soon going to be a 5 billion a year drug and they currently are valued at a market cap of 400 million. Earnings coming in the next month or so currently trading at 1.80 but based on just the billion a year it should be at least $14 right now. Don’t miss out
Honestly. This one has been on my watch list for a while now. Think there is potential. Always a good amount of risk with bio stocks (I am on ARDX and AQST… and watching MIST and AKBA also). May open up a position soon once I free up some funds from other plays. Good luck!
ACRS, PL, AKBA are my best performers.
u/eddieJacks1 do you think its a good idea to buy AKBA right now? i am new to this and relying on these communities and commentary (also Yahoo finance). Analysts are rating it as a "Strong Buy"
Has your view on AKBA changed since this comment
The penny stocks I’m in KULR, ELTP, SLI, and AKBA. That’s just in my play around account. My 401K and Roth are VTI, FXAIX, and a few other funds with smaller % total of my portfolios.
Hi. Coherus I am out, but will get back in soon. Still like it. They had some issues, as all Bio does, but like AKBA, still very Bullish. As to FGEN, pure "as I see it". It is all in the text. The problem is patent expiry, so a lot does hinge on that approval for the next indication in China. My favorite now is SLS.
Sure! AKBA: Akebia Therapeutics, Inc. (AKBA) is showing strong bullish momentum, with the current price at $1.64 significantly above its 30-day SMA of $1.353 and an RSI indicating overbought conditions across multiple timeframes. The MACD histogram is positive, suggesting continued upward momentum. Despite the lack of recent news, the stock's volume surge in recent days indicates heightened interest, possibly driven by speculative trading or anticipation of upcoming catalysts. Given the broader market's cautious optimism, AKBA may benefit from the tech and healthcare sector's resilience. For today's session, consider entering around $1.62, targeting $1.75 as the first price target and $1.85 as the second, with a stop loss at $1.50 to manage downside risk. Confidence in reaching the first target is high due to technical indicators, while the second target carries moderate confidence given potential market volatility. BLRX: BioLineRX Ltd (BLRX) is currently trading at $0.4501, showing a bearish trend with declining momentum as indicated by the RSI values below 35, suggesting oversold conditions. The stock has been on a downward trajectory, with the 10-day SMA ($0.4633) and 20-day EMA ($0.5023) both above the current price, indicating potential resistance levels. The MACD histogram is slightly positive, hinting at a possible short-term consolidation or minor rebound. Given the lack of recent news and low trading volume, the stock may continue to face selling pressure. For today's session, consider entering a short position around $0.455, with a first target of $0.440 and a second target of $0.430. Set a stop loss at $0.465 to manage risk. Confidence in reaching the first target is moderate due to the oversold RSI, while the second target carries lower confidence given potential support near $0.440. ZIM: ZIM Integrated Shipping Services Ltd. (ZIM) is showing strong bullish momentum, with the current price at $24.41, significantly above its 10-day SMA of $21.30 and 20-day EMA of $21.53, indicating a robust uptrend. The RSI values are in the overbought territory, suggesting potential for continued upward movement but also caution for a pullback. The MACD histogram is positive, reinforcing bullish sentiment. Given the broader market's cautious optimism, ZIM's recent volume surge and technical indicators suggest a favorable environment for a long position. Enter around $24.40, targeting $25.00 as the first price target with high confidence due to strong momentum, and $25.50 as the second target with moderate confidence considering potential resistance. Set a stop loss at $23.80 to manage downside risk. This analysis assumes no significant negative news impacting the shipping sector today.
AKBA 
Sure! BLRX: BioLineRX Ltd (BLRX) is currently trading at $0.4759, showing a bearish trend with significant downward momentum as indicated by the RSI values below 30, suggesting oversold conditions. The MACD histogram is negative, reinforcing the bearish sentiment. The stock has been under pressure, with the 10-day SMA ($0.4849) and 20-day EMA ($0.5366) both above the current price, indicating potential resistance levels. Given the lack of recent news and low trading volume compared to its 65-day average, the stock may continue to face selling pressure. In the broader market context, the cautious optimism and mixed signals from major indices could further impact BLRX negatively, especially if macroeconomic headwinds persist. For today's session, consider entering a short position around $0.4759, with a first target of $0.46 and a second target of $0.44, setting a stop loss at $0.49. Confidence in reaching the first target is moderate due to technical indicators, while the second target carries lower confidence given potential volatility and market unpredictability. FRSX: BioLineRX Ltd (BLRX) is currently trading at $0.4759, showing a bearish trend with significant downward momentum as indicated by the RSI values below 30, suggesting oversold conditions. The MACD histogram is negative, reinforcing the bearish sentiment. The stock has been under pressure, with the 10-day SMA ($0.4849) and 20-day EMA ($0.5366) both above the current price, indicating potential resistance levels. Given the lack of recent news and low trading volume compared to its 65-day average, the stock may continue to face selling pressure. In the broader market context, the cautious optimism and mixed signals from major indices could further impact BLRX negatively, especially if macroeconomic headwinds persist. For today's session, consider entering a short position around $0.4759, with a first target of $0.46 and a second target of $0.44, setting a stop loss at $0.49. Confidence in reaching the first target is moderate due to technical indicators, while the second target carries lower confidence given potential volatility and market unpredictability. AKBA: Akebia Therapeutics, Inc. (AKBA) is currently trading at $1.32, with technical indicators suggesting a neutral to slightly bearish outlook. The 10-day SMA is below the 20-day and 30-day SMAs, indicating potential downward pressure. The MACD histogram is negative, reinforcing this bearish sentiment. RSI levels are hovering around neutral, suggesting limited momentum in either direction. Given the broader market's cautious optimism and AKBA's lack of recent news, expect range-bound trading with potential downside. For today's session, consider entering a short position around $1.32, targeting $1.28 as the first price target and $1.25 as the second, with a stop loss at $1.35. Confidence in reaching the first target is moderate due to current technical signals, while the second target carries lower confidence given potential market volatility. RIVN: Rivian Automotive (RIVN) is currently trading at $10.36, showing a significant downtrend over the past month, with technical indicators like the RSI hovering around 33, indicating oversold conditions. The MACD histogram is slightly positive, suggesting potential for a minor rebound, but the overall sentiment remains bearish due to production challenges and financial losses highlighted in recent news. The stock's 10-day SMA of $10.479 is below its 20-day and 30-day SMAs, reinforcing the downward momentum. Given the broader market's cautious optimism and Rivian's specific supply chain issues, expect further downside pressure. For today's session, consider entering a short position around $10.40, with a first price target of $10.00 and a second target of $9.75. Set a stop loss at $10.60 to manage risk. Confidence in reaching the first target is moderate due to oversold conditions, while the second target carries lower confidence given potential for short-term rebounds.
Label is similar to the current ESAs. Getting nephrologist and dialysis organizations to use vafseo will be the key. TDAPA benefits for those groups kick in starting January 1. There is a financial incentive to use Vafseo instead of ESAs beginning January 1, so with a similar label than the current standard of care, those groups may start to use Vafseo in order to gain the financial incentive twice of TDAPA. We will see but it’s all lining up to be very positive for AKBA.
The OS is enormous, the company would benefit from a reverse split to be able to further raise cash. Inside ownership and institutional, low. Maxim Group an analyst, always a red flag. Combined with HC Wainright no less, a combination of toxicity. These two will drop the SP if it suits them. Huge cash burn. Compliance must be met by September 9th. So it has to stay above 1$ for 10 days in a span of 25 days (or less). Look at XFOR or AKBA, massive drops after approvals. On boards like Yahoo, Twits and Reddit retail was going nuts (including myself). The opposite of what was expected happened. What is important is the time of approval to to market and first revenue, often this is a period of 12 - 24 months. This all said, I might be wrong. Good luck
how did i end up long on so many biotechs like if NVAX finally gets a 100% efficacy covid vaccine, SMMT cures cancer and so does AZN, CRVO cures alzheimer's, and AKBA does...whatever i thought it was gonna do, i'm scrooge mcduck but if all that happens soon biden might re-enter the race lol
Phenomenal work, thanks! I've been holding AKBA for the last 2 years
Your analysis of AKBA's market potential and pricing strategy is spot-on. With their connections to Fresenius and other renal centers, plus potential approval for NDD patients, AKBA could really soar. I will be keeping an eye on regulatory milestones and market dynamics will be key. Cheers to AKBA’s growth prospects!
If AKBA can achieve a 20% market penetration with Vafseo in the US alone, a price target of $25 - $30 is justified as fair market value. That's calculated based on WAC pricing minus 15% rebate during TDAPA then $3,000 per year per patient to match ESA. If AKBA gains approval for NDD patient population, the price target goes up to $50 - $60. AKBA does not need to be bought out to see it hit $10+ a share in the next 12 months, in my opinion. Do your own research and calculations on revenue though. not financial advice.
AKBA (Akebia) is going to the fucking moon tomorrow. Up 9% today and I am 100% certain we are in for some at least 500% gains tomorrow. You guys need to trust me on this I can not give any more information just do not miss out on this. We will see the stock go to at least $5 tomorrow but it is going to continue to drive up for the next year to come. DO. NOT. MISS. OUT. ON. THIS.
AKBA (Akebia) is going to the fucking moon tomorrow. Up 9% today and I am 100% certain we are in for some at least 500% gains tomorrow. You guys need to trust me on this I can not give any more information just do not miss out on this. We will see the stock go to at least $5 tomorrow but it is going to continue to drive up for the next year to come. DO. NOT. MISS. OUT. ON. THIS.
AKBA is going to the fucking moon. Up 9% today and still pumping after hours. Will be at least a 10 bagger tomorrow
Two stocks I invested in were AKBA and another one. Both are at - 50%.
I’m in long term for AKBA, DNA, and KULR :)
Should probably do your own research instead of asking others to tell you since most will pump their own stocks. Ones I am watching currently are - Kulr (I own a lot of shares just to disclose) - Laes (speculative semi conductor company) - Llap (Satellites, won’t be a penny for long) - Hubc (Israeli defence company) - Blue (Gene editing company, main competitor is CRISPR which trades 50x the price of blue, risky but worth the risk for me) - ABAT - AKBA - VXRT - DNA (high risk speculative, be careful) - not sure if it counts as penny but RKLB Point being there’s a lot you can find just gotta dig deep. I only own kulr atm
AKBA 
Only down 15% with AKBA? I also have FGEN, PALI, and VTGN.
I think an important thing to note is they dropped the FDA news during -early- premarket so it pumped a tiny bit before returning to "normal price". Because not many people can buy premarket it ends up spreading out buyers and doesn't have as much of a huge pump. I'm pretty sure the same thing happened with AKBA a little while ago. If they dropped news at market open I'm almost positive it would have pumped hard
AKBA crashed after approval a few weeks ago
Are people worried about XFOR pulling an AKBA?
But with AKBA, they actually are profitable, which is rare for biopharma. It's not just wishful thinking that we make our money back, and then some it just will take a lot longer. But with FGEN...I an just dreaming. I am having fun with CZOO today sold this morning for a profit and bought at 10.30 with another order if it hits 10.20. I plan riding the waves until their earnings. It's much less stressful to jump in and out for a $1 per share gain each day. I need to find more squeeze plays that pumpers bailed on.
Sold mine for more SLS. I too held AKBA too long. ICU bag holder here too.
I learned that last month AKBA. We were are supposed to sell before the announcement. I have doubled and am now waiting on earnings next month.
AGRI pre market buy and sell. Try to finally get rid SMFL Buy more AKBA.
I am running into the same issues with all biopharms. I am waiting on the earnings date for AKBA. But I don't know exactly what will change the tide.
$AKBA seems to have bottomed out at 1.33 and moving up intraday
Sell 2 days before approval, maybe See: AKBA, double top before approval, 2 days before was safer
AKBA similar narrative
This. Additionally, and while I don’t have an option chain for AKBA in front of me, typically spreads are wide and volume small. Getting your calls at $0.35 can be hard. Remember your example was for $750. To do this for a real amount of money you are going to need hundreds of contracts and that will likely move the price.
Nasty dip today for $XFOR but still holding till PDUFA, anyone got a reason of why it dipped or is it just a “it is what it is” kind of dip? Shorts volume and borrowing fees have increased for $XFOR, nothing to worry about it - usually increases anyways, they just expect it to tank once approval is given - see $ICU, $AKBA, $OPTN.
I like how you say its a text book shitty biotech stock despite being completely clueless about the company. AKBA just had its primary drug approved by the FDA.
What you ought to consider is what I call the aggressive compounder. Take the premium earned and buy more shares in AKBA until you have another 100 shares and then keep going...
Yes that is how call options work and the risks are all still what you would find in any article about this strategy. If the stock moves in a straight line for 24 months and you sell those calls and wait 6 months to expiry every time you would make $750, what you put in. But say your calls expire worthless the first time making$175 but AKBA is now trading at $1. Do you sell more calls at a lower strike? Do you try selling $2 calls for .05 each, their likely price at that time? Do you wait and still lose money, not knowing if it will ever reach $1.50 again?
Daprodustat, sold as Jesduvroq, is another oral HIF-PF inhibitor that treats anemia caused by CKD. Like AKBA's drug, it's only sold in dialysis-dependent patients and has a black box. The big difference is that drug is owned by GlaxoSmithKline, which has much more money to market the drug. Anyways, [they scrapped plans](https://www.fiercepharma.com/pharma/gsk-scraps-plan-launch-oral-anemia-drug-eu-ceases-further-expansion) to expand the drug globally because the drug is selling so poorly. Auryxia loses its patent in 2025. It's over.
AKBA nearing a decent buy price, around same level as before price rise
I feel like everyone assumed ICU and AKBA would get approved and the price went up right until the decision and then went down so as long as you got in prior and got out after you made money. I know I did.
I think $AKBA is gonna make a come bAKBA. Long term prospects of the company are pretty good. I threw $200 at it because there's no way all the pharmaceutical revenue they generate won't make them a lot of immediate money.
I lost a lot on AKBA and don't want to sell at loss now... Hope it will recover but it might take some time
Is AKBA still a long term hold? Everything about the company sounds fairly positive to me, but the stock just keeps plummeting.
So when's my AKBA gonna moon...?
I hope so too. I lost a lot on AKBA so I have to hold it lol.
I'm holding AKBA. I can't see a stock that just got FDA approval and a nice institutional investment going backwards. It looks like people are impatient and taking profits or moving money. Might take a while but I'm sure it's going to go up.
Need $AKBA to rebound from last Thursday. It was $2.75 in pre- hours Thursday morning. Now at $1.83
XFOR. Upcoming FDA decision on 4/30. Rolled AKBA gains into this on the dip last Friday at $1.30
Do your research but if you ask about my experience it was very great, $TT00, $ICU, $OPTN, $AKBA. But again do your own research and how does the approval affect the company? What is the product? Is it already existing in the market? Are they likely to get approved? These questions and all reasonable questions will give you the answer if you should get in or not.
Algos. I've had this happen to quite a few stocks I watch. Check AKBA. Barcoded at 1.80 for hours.
Man I am an idiot, sold my $AKBA profit bought $AVTX at $25, put a stop a loss at $24, it hit within a couple of minutes, and then a couple hours later I see it trading at $33 perfect lol Anyways your boy upgraded to $IBRX and $AQST PDUFA plays a month early is fun. Also still holding $PTPI, just drop some news please
these things are hard to tell, I just hold through earnings. Just like AKBA.... Needs time
Why is AKBA dumping? Would have expected the FDA approval to be a major catalyst
Opinions on selling $AKBA? Bought as a swing trade yesterday idk if it’ll hit $3+ today or go red
Made a profit on $VLD before it drove off a cliff. Holding 3k shares, waiting on the long term return. Bought $3000 worth of $AKBA, excited for this take off. How's everyone else feeling?
AKBA is going to blow today or what?
AKBA got its FDA approval. Could be good.
What we expectin for AKBA tomorrow, since FDA
$AKBA will probably do something interesting tomorrow Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis https://ir.akebia.com/news-releases/news-release-details/akebia-receives-fda-approval-vafseor-vadadustat-tablets
AKBA - approval priced in already or is this potentially mooning after close?